Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Demographics of participants

From: Serum proBDNF/BDNF and response to fluvoxamine in drug-naïve first-episode major depressive disorder patients

  Values
Age (years) 38 (19)
Female (%) 62
Daily dose at week 4 (max) (mg) 103 (38)
DUP (months) 2.1 (0.9)
HAMD17 (baseline) 19.3 (2.8)